Interesting MCK Put And Call Options For August 2026

McKesson (MCK) is trading at $817.35 with a $810 put bid at $61.60 (sell-to-open cost basis $748.40) implying a 1% OTM put and a 59% probability of expiring worthless; that premium equates to a 7.60% return on cash (11.29% annualized). On the call side, the $850 strike bid is $65.00 for an Aug-2026 covered-call that would deliver a 11.95% total return if called, with a 49% chance to expire worthless and a 7.95% premium boost (11.80% annualized). Implied vol is ~29% vs. trailing 12-month vol of 23%, and the piece frames these as income-generation trade ideas rather than company-specific fundamental news.

Analysis

Market structure: The current MCK option setup favors short-premium strategies — selling the Aug 2026 $810 put collects $61.60 (cost-basis if assigned $748.40) and selling the $850 call collects $65 on $817.35 stock. Implied vol ~29% vs 12‑month realized ~23% signals options are modestly rich (~+6ppt); institutional cash-secured put sellers and covered-call income buyers are the immediate beneficiaries, while long-dated call buyers pay for optionality.

Risk assessment: Tail risks include regulatory moves on drug distribution/price transparency or major litigation (opioid-like) that could compress multiples >20% in adverse scenarios; market-impactful catalysts in the next 90–180 days are earnings, Medicare policy updates, or large customer contract changes. Short-term (days–weeks) payoff is premium capture and IV mean reversion; medium-term (3–12 months) depends on revenue mix and margin recovery; long-term risk tied to secular healthcare distribution consolidation.

Trade implications: Direct actionable: cash‑secured put at $810 or a short put spread ($810/$740) to cap downside — target position size 1–3% notional, roll or buy back if stock < $740 or IV falls <22%. Consider covered-call ($850) if long stock for ~12% max upside through Aug 2026, or replace with a collar (buy $740 put) if assignment risk unacceptable. Use IV rank (>50%) as sell trigger; close or hedge if IV compresses >8pt or stock gaps >9%.

Contrarian angles: Consensus underweights regulatory binary risk vs option sellers; implied yield (~7.6–7.95%) understates discovery risk if a 10–25% adverse event occurs. Historical precedent: distributor litigation compressed peers by 20–40% over 6–24 months; therefore prefer defined-risk short strategies (credit spreads) over naked puts and size positions to withstand assignment capital needs.

Key Decisions for Investors

• Establish a 1–2% portfolio allocation via cash‑secured puts: sell Aug 2026 MCK $810 puts at ~$61.60 (net effective cost if assigned $748.40). Size so max capital at risk ≤2% of portfolio; buy to close or convert to a $810/$740 put spread if MCK < $740.
• If already long MCK, sell the Aug 2026 $850 covered call for ~$65 to lock ~11.95% gross upside to expiry; simultaneously buy a $740 Jan 2027 put if downside protection to -9% is desired (construct a collar), cost funded by rolling down calls.
• Prefer defined-risk credit spreads over naked short puts: short $810/$740 put spread (debit = max loss - premium) to limit tail exposure. Exit or hedge if IV falls below 22% or stock gaps down >9% intraday.
• Pair trade (relative value): go long MCK vs short CAH or ABC if MCK fundamentals (EBITDA margin, revenue growth) confirm outperformance; size 0.5–1% net long and rebalance quarterly, target spread convergence of 5–10% over 6–12 months.